Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1x1 Forum
06 oct. 2022 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022
14 sept. 2022 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
22 août 2022 01h00 HE
|
Tessa Therapeutics Ltd
Seasoned pharmaceutical industry executive to lead Tessa’s corporate and development strategy built around its proprietary autologous and allogeneic CAR-T platforms Appointment follows Tessa’s...
Tessa Therapeutics Doses First Patient in Phase 1b Clinical Trial Investigating TT11 in Combination with Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL)
17 août 2022 06h00 HE
|
Tessa Therapeutics Ltd
Phase 1b clinical trial (ACTION) designed to evaluate TT11 as a potential second-line therapy TT11, Tessa’s autologous CD30-CAR-T therapy, is also being investigated as a monotherapy in the treatment...
Tessa Therapeutics to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas at the SDCT-REMEDIS Cell Therapy Conference 2022
13 juin 2022 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, June 13, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
09 juin 2022 06h00 HE
|
Tessa Therapeutics Ltd
Proceeds to fund clinical development of Tessa’s autologous (TT11) and allogeneic (TT11X) cell therapy programs Amy Schulman and Darren Carroll from Polaris Partners have joined Tessa’s Board of...
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
04 avr. 2022 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, April 04, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
Tessa Therapeutics Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma at 2021 ASH Annual Meeting
13 déc. 2021 18h00 HE
|
Tessa Therapeutics Ltd
Oral poster highlights data from 14 heavily pre-treated patients enrolled in pilot stage of multicenter, open-label, single arm CHARIOT study to evaluate safety and efficacy of TT11 TT11 demonstrated...
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
11 déc. 2021 18h00 HE
|
Tessa Therapeutics Ltd
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results...
Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting
03 nov. 2021 06h00 HE
|
Tessa Therapeutics Ltd
SINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...